Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies …
P Rodriguez-Otero, S Usmani, AD Cohen… - The Lancet …, 2024 - thelancet.com
Multiple myeloma remains an incurable disease, despite the development of numerous drug
classes and combinations that have contributed to improved overall survival …
classes and combinations that have contributed to improved overall survival …
[HTML][HTML] Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
M Wang, C Wang, J Deng, H Wang, C Sun… - Frontiers in Bioscience …, 2024 - imrpress.com
The treatment options for multiple myeloma (MM) have undergone significant transformation
with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive …
with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive …